Systems (Nasdaq:KRMD) announced today that it signed a development agreement with a global pharmaceutical company.

The SCIg market is growing rapidly, with KORU Medical Systems outperforming competitors by capturing market share. Read why I ...

Systems announced the signing of an agreement with a global pharmaceutical company. The agreement is intended for KORU ...

Several intravenous and subcutaneous Ig (SCIg) preparations are available either ... approved maximum infusion rate and excipients. [51–53] All these factors may contribute to treatment efficacy ...

KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and ...

Systems (NASDAQ: KRMD), a medical technology firm with a market capitalization of $194 million, announced a partnership with a global pharmaceutical manufacturer to conduct a Phase III clinical trial.

The Insignis Syringe Infusion System is a robust ... effective for patients requiring subcutaneous immunoglobulin (SCIg) for Primary or Secondary Immune Deficiency and neuromodulation therapies.